Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH.

Oncoimmunology. 2012 May 1;1(3):287-357.

2.

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A.

J Immunother. 2008 Apr;31(3):294-309. doi: 10.1097/CJI.0b013e31816a8910.

3.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

4.

Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.

Pérez-Díez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B.

Cancer Res. 1998 Dec 1;58(23):5305-9.

5.

Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS.

J Immunol. 1998 Nov 15;161(10):5607-13.

6.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

7.

Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.

Naveh HP, Vujanovic L, Butterfield LH.

J Immunother Cancer. 2013 Nov 18;1:19. doi: 10.1186/2051-1426-1-19. eCollection 2013.

8.

Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.

Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD.

J Immunother. 2010 Sep;33(7):706-15. doi: 10.1097/CJI.0b013e3181eccbd4.

PMID:
20664356
9.

Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH.

Cancer Immunol Immunother. 2009 Jan;58(1):121-33. doi: 10.1007/s00262-008-0533-2. Epub 2008 May 17.

11.

Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.

Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ.

Clin Cancer Res. 2012 Oct 1;18(19):5460-70. doi: 10.1158/1078-0432.CCR-11-3368. Epub 2012 Aug 15.

12.

CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS.

Cancer Res. 2001 Dec 15;61(24):8787-93.

13.

In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.

Linette GP, Shankara S, Longerich S, Yang S, Doll R, Nicolette C, Preffer FI, Roberts BL, Haluska FG.

J Immunol. 2000 Mar 15;164(6):3402-12.

14.

Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H.

Oncology. 2005;68(2-3):163-70. Epub 2005 Jul 4.

PMID:
16006753
15.

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.

Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.

Cancer Gene Ther. 2002 Feb;9(2):202-8.

16.

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.

Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A.

Cancer Gene Ther. 2005 Jun;12(6):516-27.

PMID:
15775996
17.

Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM.

J Immunother. 1997 Jul;20(4):276-86.

18.

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchok JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW.

Clin Cancer Res. 2011 Apr 1;17(7):1984-97. doi: 10.1158/1078-0432.CCR-10-3421. Epub 2011 Feb 25. Erratum in: Clin Cancer Res. 2011 Jun 1;17(11):3851. Wolchock, Jedd D [corrected to Wolchok, Jedd D].

19.

Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

Tüting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ.

J Immunol. 1998 Feb 1;160(3):1139-47.

20.

Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.

Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, Berneman ZN, Smits EL.

Cancer Immunol Immunother. 2015 Jul;64(7):831-42. doi: 10.1007/s00262-015-1688-2. Epub 2015 Apr 12.

PMID:
25863943

Supplemental Content

Support Center